Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px
Document › Details

Argen-X N.V. (Argenx). (12/8/14). "Press Release: Argen-X Reports Preclinical Data on ARGX-110 in Chronic Myelogenous Leukemia Model". Breda & Ghent.

Organisations Organisation Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
  Today Argenx SE (Euronext + Nasdaq: ARGX)
  Group Argenx (Argen-X) (Group)
  Organisation 2 University of Bern
Products Product cusatuzumab (ARGX-110)
  Product 2 animal model
Persons Person de Haard, Hans (Argen-X 201203 CSO)
  Person 2 Swallow, Mark (Huntsworth 201101 Citigate Dewe Rogerson London)

Data to be presented at ASH demonstrate potential of ARGX-110 in reversing resistance to tyrosine kinase inhibitors

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announces the presentation of preclinical data at the American Society of Hematology (ASH) Annual Meeting highlighting the potential of the CD70 pathway as a targetable mechanism to overcome drug resistance in chronic myelogenous leukemia (CML). The data show that co-treatment of ARGX-110, the Company’s anti-CD70 therapeutic antibody, and imatinib, a first-line BCR/ABL-specific tyrosine kinase inhibitor (TKI), eradicates the disease-initiating CML stem cells, a cell population often resistant to TKI therapy.

“We are thrilled by these breakthrough findings, which add significantly to our understanding of the biology of the CD70 pathway and its role in leukemia models. The potential implication that ARGX-110 could help combat TKI resistance in leukemia is very exciting,” says Hans de Haard, Chief Scientific Officer of arGEN-X.

The presentation features preclinical data from a collaboration with the Tumor Immunology Lab led by Prof. A. F. Ochsenbein at the University of Bern that demonstrate the eradication of leukemia stem cells (LSCs) in human and murine CML models by co-treatment of ARGX-110, a CD70 blockade, and imatinib. These findings highlight that CD70/CD27 signaling is a new targetable mechanism of drug resistance in LSCs and its blockade may lead to new therapeutic strategies to overcome treatment resistance.

“We are very pleased to present these preclinical data today and believe the findings could offer a new promising treatment approach to overcome drug resistance of leukemia stem cells (LSCs). In CML, a continuous treatment with tyrosine kinase inhibitors (TKIs) is required and most patients rapidly progress after drug discontinuation. Although some mechanisms of overcoming drug resistance in LSCs have been proposed, none of these has yet been translated to a therapeutic application. With these data, we identify a targetable surface molecule, CD70, and demonstrate early signs of benefit from treatment with ARGX-110 in combination with TKIs to overcome drug resistance in CML models,” states Carsten Riether, Ph.D. at the University of Bern.

A Pharma Workshop titled, “CD70: Targeting hematological malignancies,” will take place today from 12:15pm-1:15pm PT at the W Hotel (Great Room 1) in San Francisco to further discuss the data presented above, the CD70 biology in hematological malignancies, and the ARGX-110 clinical development plan.

A live webcast will be available at

For further information, please contact:

Tim Van Hauwermeiren
Chief Executive Officer

Hans de Haard
Chief Scientific Officer

+32 9 243 40 70

arGEN-X BVBA (R&D Center)
Technologiepark 30
9052 Zwijnaarde

Mark Swallow
David Dible
Citigate Dewe Rogerson
+44 207 282 2949

Beth DelGiacco
Stern Investor Relations
+1 212 362 1200

About ARGX-110

ARGX-110 is a SIMPLE Antibody™ targeting CD70, an immune checkpoint target involved in hematological malignancies, several solid tumors and severe autoimmune diseases. ARGX-110 works in three ways: i) blocks growth of tumor cells, ii) kills cancer cells and iii) restores immune surveillance against tumors (Silence K. et al. mAbs 2014; 6 (2):523-532). ARGX-110 is currently being evaluated in hematological and solid tumors in a Phase 1b study in Europe and will be developed in partnership with the Leukemia & Lymphoma Society (LLS) for the rare lymphoma Waldenström’s macroglobulinemia.

About CML

Chronic myelogenous leukemia (CML), is a cancer of white blood cells. This leukemia is a clonal bone marrow stem cell disorder characterized by the unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. The mainstay of CML targeted therapy rests on tyrosine kinase inhibitors (TKIs), like imatinib.

About arGEN-X

arGEN-X is a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases. arGEN-X has generated a clinical pipeline of differentiated antibody candidates using its SIMPLE Antibody™ discovery platform. SIMPLE Antibody™ has a particular strength in addressing novel, complex disease targets that are difficult to access using established antibody technology platforms. Fc engineering technologies – NHance®, ABDEG™ and POTELLIGENT® – further enhance the therapeutic properties of SIMPLE Antibody™ leads in terms of their residence time in the body, their ability to clear disease targets or pathogenic antibodies and their cell killing potency through Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), respectively. arGEN-X has leveraged its suite of antibody technologies in forging strategic collaborations with pharmaceutical and biotechnology companies to provide new approaches to diseases with unmet medical needs.

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements arGEN-X makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. arGEN-X’ actual results may differ materially from those predicted by the forward-looking statements. arGEN-X undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To unsubscribe to this email service please send an email to requesting removal.

arGEN-X N.V. Willemstraat 5, 4811 AH Breda, The Netherlands arGEN-X BVBA Technologiepark 30, 9052 Zwijnaarde, Belgium

Record changed: 2017-04-17


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Argenx (Argen-X) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top